The 36-month beta value for PBM is also noteworthy at -0.48.
The public float for PBM is 9.32M, and at present, short sellers hold a 6.50% of that float. The average trading volume of PBM on October 25, 2024 was 6.09M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
PBM) stock’s latest price update
Psyence Biomedical Ltd. (NASDAQ: PBM)’s stock price has plunge by 5.21relation to previous closing price of 0.09. Nevertheless, the company has seen a -8.43% plunge in its stock price over the last five trading sessions. globenewswire.com reported 2024-10-25 that Empax Center brings significant expertise in clinical trial execution for mental health and neurological conditions Psyence Biomed on track to begin recruitment this quarter, and to announce Adjustment Disorder topline data in the second half of 2025 NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) — Psyence Group Inc (“Psyence Group”) (CSE: PSYG), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, is pleased to announce that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) (“PBM” or “Psyence Biomed”) yesterday announced the recruitment of Perth, Australia-based Empax Center as the second trial site for Psyence’s Biomed ongoing Phase IIb clinical trial of nature-derived psilocybin as a potential treatment for Adjustment Disorder in Palliative Care. According to Dr. Clive Ward-Able, Medical Director of Psyence Biomed, “Having Empax Center as our second clinical trial site adds a cutting-edge facility specializing in mental health treatments, including psychedelic-assisted therapies, and also helps position us to enroll this important study as quickly and efficiently as possible”.
PBM’s Market Performance
PBM’s stock has fallen by -8.43% in the past week, with a monthly drop of -9.60% and a quarterly drop of -84.03%. The volatility ratio for the week is 17.17% while the volatility levels for the last 30 days are 15.27% for Psyence Biomedical Ltd. The simple moving average for the last 20 days is -2.89% for PBM stock, with a simple moving average of -90.44% for the last 200 days.
PBM Trading at -52.62% from the 50-Day Moving Average
After a stumble in the market that brought PBM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.32% of loss for the given period.
Volatility was left at 15.27%, however, over the last 30 days, the volatility rate increased by 17.17%, as shares sank -7.12% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -80.99% lower at present.
During the last 5 trading sessions, PBM fell by -6.94%, in comparison to the 20-day moving average, which settled at $0.1019. In addition, Psyence Biomedical Ltd. saw -98.93% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for PBM
The total capital return value is set at 155.06. Equity return is now at value 1.27, with 1.13 for asset returns.
Based on Psyence Biomedical Ltd. (PBM), the company’s capital structure generated -19.88 points at debt to capital in total, while cash flow to debt ratio is standing at -48.2.
Currently, EBITDA for the company is -2.75 million with net debt to EBITDA at -0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.01.
Conclusion
In summary, Psyence Biomedical Ltd. (PBM) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
